J Rheumatol:使用生物制剂治疗银屑病关节炎的指炎和附着点炎

2019-03-07 xiangting MedSci原创

汇总分析表明,抗TNF-α药物与新型药物(ustekinumab、苏金单抗和ixekizumab)在指炎和附着点炎上具有相同疗效。

随机对照试验中不同作用机制的生物制剂(TNF-α抑制剂、白介素-12/23和白介素-17)对银屑病关节炎有疗效。这项研究目的是对那些药物治疗指炎和附着点炎进行汇总meta分析,并将其与美国风湿病学会20反应(ACR20)和健康评估问卷残疾指数评分(HAQ-DI)进行比较。

研究人员进行系统文献检索,并使用随机效应模型对抗TNF-α(英夫利昔单抗、戈利木单抗、阿达木单抗)、白介素-12/23(ustekinumab)和白介素-17(苏金单抗、ixekizumab)的随机对照试验进行汇总meta分析。使用Cochrane偏倚风险工具评估偏倚。

汇总分析纳入18项随机对照试验(n=6981)。在第24周时TNF-α抑制剂和新型生物制剂(ustekinumab、苏金单抗、ixekizumab)均表现出明显的指炎消除,与安慰剂比较的汇总风险比(RRs)分别为2.57(95%CI:1.36-4.84)和1.88(95%CI:1.33-2.65)。在第24周消除附着点炎,TNF-α抑制剂的RR为1.93(95%CI:1.33-2.79),新型生物制剂为1.95(95%CI:1.60-2.38)。两种类别生物制剂的ACR20反应范围有重叠(TNF-α抑制剂:RR=2.23,95%CI:1.60-3.11,白介素-12/23和-17汇总:RR=2.30,95%CI 1.94-2.72),生活质量改善评分类似,平均HAQ-DI评分变化分别为-0.29(95%CI:-0.39,-0.19)和-0.26(95%CI:-0.31,-0.22)。

汇总分析表明,抗TNF-α药物与新型药物(ustekinumab、苏金单抗和ixekizumab)在指炎和附着点炎上具有相同疗效。

原始出处:

Ahmed Mourad. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Meta-Analysis. J Rheumatol. 01 March 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718752, encodeId=231a1e18752ff, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 08 07:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825996, encodeId=ca13182599672, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Feb 11 10:53:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038253, encodeId=2950203825374, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed Jan 15 00:53:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265925, encodeId=e447126592558, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Mar 09 04:53:00 CST 2019, time=2019-03-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718752, encodeId=231a1e18752ff, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 08 07:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825996, encodeId=ca13182599672, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Feb 11 10:53:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038253, encodeId=2950203825374, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed Jan 15 00:53:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265925, encodeId=e447126592558, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Mar 09 04:53:00 CST 2019, time=2019-03-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718752, encodeId=231a1e18752ff, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 08 07:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825996, encodeId=ca13182599672, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Feb 11 10:53:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038253, encodeId=2950203825374, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed Jan 15 00:53:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265925, encodeId=e447126592558, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Mar 09 04:53:00 CST 2019, time=2019-03-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718752, encodeId=231a1e18752ff, content=<a href='/topic/show?id=5a6456425fc' target=_blank style='color:#2F92EE;'>#指炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56425, encryptionId=5a6456425fc, topicName=指炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f67632615255, createdName=xiongliangxl, createdTime=Fri Mar 08 07:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825996, encodeId=ca13182599672, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Tue Feb 11 10:53:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038253, encodeId=2950203825374, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed Jan 15 00:53:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265925, encodeId=e447126592558, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Mar 09 04:53:00 CST 2019, time=2019-03-09, status=1, ipAttribution=)]
    2019-03-09 lmm397

相关资讯

Ann Rheum Dis:银屑病关节炎中滑膜组织多功能T细胞与DAPSA的关联

这些数据证明,PsA滑膜组织中多功能T细胞的富集与DAPSA和离体治疗反应密切相关。

J Rheumatol:银屑病关节炎患者使用TNFi达到缓解的预测因子

根据CDAI标准,基于美国的登记中少数PsA患者达到缓解。女性、肥胖、合并症和教育程度对使用TNFi能否达到缓解有影响。

J Rheumatol:银屑病关节炎患者的负担和疾病特征

不同严重程度PsA患者的疾病负担都很明显。相当一部分PsA患者未接受过抗银屑病治疗。

Arthritis Rheumatol:依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效

联合甲氨蝶呤和依那西普并未改善依那西普的疗效。

Ann Rheum Dis:早期使用TNF抑制剂有助于银屑病关节炎的缓解

在早期PsA患者中,第22周戈利木单抗+MTX的DAS缓解率几乎是单用MTX的2倍。

Arthritis Rheumatol:银屑病关节炎相关新型自身抗体的识别

这项研究结果表明,这些自身抗体可能是有用的生物标志物,并提示了银屑病和银屑病关节炎的治疗靶点。